AXBERI HP 150 MG — DIN 02540037
ENOXAPARIN SODIUM : 150 MG · BAXTER CORPORATION · SOLUTION · wholesale supply in Canada
Health Canada status: MARKETED
What is AXBERI HP?
AXBERI HP 150 MG contains ENOXAPARIN SODIUM : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02540037, held by BAXTER CORPORATION, supplied as SOLUTION for SUBCUTANEOUS ; INTRAVENOUS administration. Health Canada currently lists it as marketed, status dated 15-Oct-2024. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
How much does Enoxaparin cost around the world?
Enoxaparin is listed on 5 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Greece publishes a producer price (ex-factory); Hungary publishes a producer price (ex-factory); Romania publishes a max producer price. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 8 | 107 | USD███.██ |
| Hungary | producer price (ex-factory) | 21 | 28 | HUF███.██ |
| Greece | producer price (ex-factory) | 16 | 16 | EUR███.██ |
| Romania | max producer price | 6 | 8 | RON███.██ |
| South Africa | single exit price | 6 | 6 | ZAR███.██ |
165 pack listings across 57 brand entries and 4 price bases, refreshed 03 Sep 2026. Ranges span every Enoxaparin pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Enoxaparin in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
6 holders have a Canadian DIN containing Enoxaparin, across 46 DINs, of which 44 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| SANOFI-AVENTIS CANADA INC | 9 | 8 | LOVENOX, LOVENOX HP, LOVENOX WITH PRESERVATIVE 300MG/3ML | Sourceable in Canada |
| SHENZHEN TECHDOW PHARMACEUTICAL CO., LTD. | 8 | 8 | REDESCA, REDESCA HP | Sourceable in Canada |
| JUNO PHARMACEUTICALS CORP. | 8 | 7 | NOROMBY, NOROMBY HP | Sourceable in Canada |
| BAXTER CORPORATION | 7 | 7 | AXBERI, AXBERI HP | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 7 | 7 | ELONOX, ELONOX HP | Sourceable in Canada |
| SANDOZ CANADA INCORPORATED | 7 | 7 | INCLUNOX, INCLUNOX HP | Sourceable in Canada |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 150 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | SUBCUTANEOUS ; INTRAVENOUS |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Enoxaparin |
|---|---|
| ATC code | B01AB05 |
| Biosimilar biologic | Yes |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02540037 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2540037 |
| Brand name | AXBERI HP |
| Generic / active ingredient | ENOXAPARIN SODIUM : 150 MG |
| Market authorization holder | BAXTER CORPORATION |
| Health Canada schedule | Prescription |
| ATC code | B01AB05 |
| ATC anatomical main group | B — Blood and blood-forming organs |
| ATC therapeutic subgroup | B01AB |
| Current status | MARKETED |
| Status date | 15-Oct-2024 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
44 of 46 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| AXBERI | 80 MG / 0.8 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02540010 |
| AXBERI | 40 MG / 0.4 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02539985 |
| AXBERI | 100 MG | SOLUTION | BAXTER CORPORATION | MARKETED | 02540045 |
| AXBERI | 60 MG / 0.6 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02540002 |
| AXBERI | 30 MG / 0.3 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02539977 |
| AXBERI HP | 120 MG / 0.8 ML | SOLUTION | BAXTER CORPORATION | MARKETED | 02540029 |
| ELONOX | 30 MG / 0.3 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02532247 |
| ELONOX | 40 MG / 0.4 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02532255 |
| ELONOX | 80 MG / 0.8 ML | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02532271 |
| ELONOX | 100 MG | SOLUTION | FRESENIUS KABI CANADA LTD | MARKETED | 02532298 |
2 · Same class — other molecules in ATC B01AB
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Enoxaparin | AXBERI · AXBERI HP · ELONOX · ELONOX HP · +9 more | 46 | 44 | Yes |
| Tinzaparin | INNOHEP · INNOHEP DISP.SYR.-11700 ANTI-XA IU/ML · LOGIPARIN LIQ SC 10000 FXAIU/ML | 13 | 11 | Yes |
| Heparin | CALCILEAN INJ 20000UNIT/0.8ML · CALCIPARINE INJ 20000IU/AMP · CALCIPARINE INJ 5000IU · HEPALEAN 10,000 USP · +17 more | 32 | 10 | Yes |
| Dalteparin | FRAGMIN · FRAGMIN INJ.-LIQ 2500 IU(ANTI-XA)/ML | 13 | 10 | Yes |
| Heparin, Combinations | HEPARIN SOD AND 0.9% SOD CHLORIDE INJ · HEPARIN SODIUM & 5% DEXTROSE INJECTION LIQ · HEPARIN SODIUM & DEXTROSE 5% IN VIAFLEX LIQ · HEPARIN SODIUM 20000UNITS IN 5% DEXTROSE INJ · +4 more | 8 | 4 | Yes |
| Antithrombin | ANTITHROMBIN III IMMUNO · ANTITHROMBIN III NF · THROMBATE III · THROMBATE III PWS IV 1000IU/VIAL · +1 more | 7 | 2 | Yes |
| Danaparoid | ORGARAN | 1 | 1 | Yes |
| Nadroparin | FRAXIPARINE · FRAXIPARINE FORTE | 8 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
3 · Adjacent classes in ATC B01A
| ATC subgroup | Molecules | DINs | Marketed |
|---|---|---|---|
| B01AF | Apixaban · Edoxaban · Rivaroxaban | 159 | 121 |
| B01AC | Abciximab · Acetylsalicylic Acid · Cangrelor · Clopidogrel · Combinations · +10 more | 158 | 66 |
| B01AA | Acenocoumarol · Warfarin | 62 | 16 |
| B01AE | Argatroban · Bivalirudin · Dabigatran Etexilate · Lepirudin | 18 | 11 |
| B01AX | Caplacizumab · Defibrotide · Fondaparinux | 10 | 5 |
| B01AD | Alteplase · Ancrod · Anistreplase · Drotrecogin Alfa · Reteplase · +3 more | 22 | 4 |
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.